Indaptus Therapeutics (NASDAQ:INDP) Trading 2.9% Higher – Here’s Why

Indaptus Therapeutics, Inc. (NASDAQ:INDP)’s stock price traded up 2.9% during mid-day trading on Monday . The stock traded as high as $0.48 and last traded at $0.48. 60,922 shares traded hands during trading, a decline of 57% from the average session volume of 141,502 shares. The stock had previously closed at $0.46.

Indaptus Therapeutics Stock Up 2.9 %

The stock has a market cap of $6.85 million, a P/E ratio of -0.28 and a beta of 1.62. The business has a 50 day moving average price of $0.76 and a 200 day moving average price of $0.98.

Indaptus Therapeutics (NASDAQ:INDP) last posted its quarterly earnings results on Thursday, March 13th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.03. On average, research analysts expect that Indaptus Therapeutics, Inc. will post -1.79 earnings per share for the current fiscal year.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.